Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK
One of the most secretive biotech candidates to lead the development of a new mRNA vaccine to fight Covid-19 just filed their IPO papers for Nasdaq.
CureVac, which has been slow to reveal details about its bid to develop a new Covid-19 vaccine, outlined a slate of alliances — including the news that its $1.8 billion deal with Eli Lilly is kaput — with a host of global players involved in its bid to cut to the front of the pack in mRNA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.